{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T22:22:40Z","timestamp":1781389360802,"version":"3.54.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2025,9,2]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">In this post hoc analysis of the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, we evaluated the efficacy of alirocumab in patients with probable heterozygous familial hypercholesterolemia (HeFH) or type III hyperlipoproteinemia (T3HLP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Patients had clinical HeFH if baseline low\u2010density lipoprotein cholesterol was \u2265250 mg\/dL and the qualifying acute coronary syndrome event occurred before age 55 (men) or 60\u2009years (women), or if baseline low\u2010density lipoprotein cholesterol was \u2265330 mg\/dL. Patients had T3HLP if the ratio, validated using the UK Biobank database, of non\u2013high\u2010density lipoprotein cholesterol\/apolipoprotein B was &gt;2.6. Genetic variation affecting low\u2010density lipoprotein cholesterol levels (HeFH) and\n                      <jats:italic toggle=\"no\">APOE<\/jats:italic>\n                      genotypes (T3HLP) was assessed in a pharmacogenomics subgroup.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      In total, 5.8% of patients from ODYSSEY OUTCOMES and 5.9% from the pharmacogenomics subgroup qualified as having clinical HeFH. In the pharmacogenomics subgroup, 295 patients (2.5%) had genetically confirmed HeFH; 45.8% also qualified as having clinical HeFH. Lipid responses and clinical benefits of alirocumab were similar in all patients with or without HeFH. In the ODYSSEY OUTCOMES cohort, 30 of 18\u2009924 patients (0.16%) were identified as having T3HLP. The pharmacogenomics subgroup included 13 of these 30 patients, of whom 7 (53.8%) were\n                      <jats:italic toggle=\"no\">APOE2\/2<\/jats:italic>\n                      homozygotes. Lipid responses to alirocumab in patients with T3HLP were comparable with those in the general population. In those with genetic dyslipidemia, adverse event incidence was similar to the overall group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">In ODYSSEY OUTCOMES, individuals with HeFH were common while those with T3HLP were rare. In their lipid responses, carriers of both conditions benefited from alirocumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Registration<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">https:\/\/clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique identifier: NCT01663402.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.124.041190","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:19:46Z","timestamp":1755926386000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial"],"prefix":"10.1161","volume":"14","author":[{"given":"Gregory P.","family":"Geba","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7844-7537","authenticated-orcid":false,"given":"Kusha A.","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4995-908X","authenticated-orcid":false,"given":"Amy","family":"Damask","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-3561","authenticated-orcid":false,"given":"Charles","family":"Paulding","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca A.","family":"Lotta","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hindy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-6795","authenticated-orcid":false,"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5491-1032","authenticated-orcid":false,"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-3287","authenticated-orcid":false,"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine","place":["Winston\u2010Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-850X","authenticated-orcid":false,"given":"Vera A.","family":"Bittner","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham","place":["Birmingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0046-0264","authenticated-orcid":false,"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine","place":["Aurora, USA"]},{"name":"Downstate Health Sciences University","place":["Brooklyn, USA"]},{"name":"University of Colorado School of Medicine","place":["Aurora, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-0695","authenticated-orcid":false,"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine","place":["Aurora, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6896-2941","authenticated-orcid":false,"given":"Ph. Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris\u2010Cit\u00e9, Institut Universitaire de France, Assistance Publique\u2010H\u00f4pitaux de Paris, H\u00f4pital Bichat, FACT (French Alliance for Cardiovascular Trials), and INSERM U1148","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8145-8034","authenticated-orcid":false,"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc.","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv370"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.12.020"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801174"},{"key":"e_1_3_2_6_2","unstructured":"World Health Organization . Familial Hypercholesterolaemia (FH): Report of a second WHO consultation. 1998 Accessed June 27 2025. https:\/\/iris.who.int\/bitstream\/handle\/10665\/66346\/WHO_HGN_FH_CONS_99.2.pdf."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.3206"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013225"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.2289"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)32417-2"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000316"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.10.001"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2016.07.007"},{"key":"e_1_3_2_14_2","unstructured":"Bristol\u2010Myers Squibb . PRAVACHOL (pravastatin sodium) tablets prescribing information. 2020. Accessed June 27 2025. https:\/\/packageinserts.bms.com\/pi\/pi_pravachol.pdf."},{"key":"e_1_3_2_15_2","unstructured":"Pfizer Inc . LIPITOR\u00ae (atorvastatin calcium) tablets prescribing information. 2009. Accessed June 27 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020702s056lbl.pdf."},{"key":"e_1_3_2_16_2","unstructured":"AstraZeneca . CRESTOR (rosuvastatin calcium) tablets prescribing information. 2016. Accessed June 27 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021366s033lbl.pdf."},{"key":"e_1_3_2_17_2","unstructured":"Quallent Pharmaceuticals Health LLC . Simvastatin pack insert. 2022. Accessed June 27 2025. https:\/\/www.quallentpharmaceuticals.com\/pdf\/Simvastatin%20PI.pdf."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9150(03)00136-9"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196701052760107"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-82-2-158"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2007.07.006"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.09.006"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.279422"},{"key":"e_1_3_2_24_2","unstructured":"Athero.org.au . Supporting documentation for the manual calculation of the Dutch Lipid Clinic Network Score (DLCNS). 1999. Accessed June 27 2025. https:\/\/www.athero.org.au\/fh\/wp\u2010content\/uploads\/Supporting\u2010Documentation\u2010for\u2010the\u2010manual\u2010calculation\u2010of\u2010DLCNS.pdf."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13742-015-0047-8"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/519795"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3656"},{"key":"e_1_3_2_28_2","unstructured":"Statgen . Minimac4. 2022. Accessed June 27 2025. https:\/\/github.com\/statgen\/Minimac4."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03205-y"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2797"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2015.09.001"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2021.09.012"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1222"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2010.01.004"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001779"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0579-z"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.01.060"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV17063"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.09.052"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2018.03.088"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-019-00166-7"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2022.03.003"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0324-9"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01018-6"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.124.041190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:47:18Z","timestamp":1762930038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.124.041190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":44,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,9,2]]}},"alternative-id":["10.1161\/JAHA.124.041190"],"URL":"https:\/\/doi.org\/10.1161\/jaha.124.041190","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]},"assertion":[{"value":"2025-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e041190"}}